Friday Furnace

Conduent replaced its maturing revolving credit facilities with a $447 million, tiered first-out/second-out structure maturing May 2029, hiring Lazard as advisor and routing the deal through two newly created subsidiary borrowers. Buried in the new agreement is a hard covenant: if Conduent does not secure at least $100 million in a securitization or receivables financing facility by December 31, 2026, it triggers an event of default. A short-lived October 14 amendment extending maturities by just 15 days confirmed the deal had been in negotiation while the original facilities were about to expire, and the new terms arrived one week after Conduent agreed to fund an $80 million cybersecurity class-action settlement.

LUMN Lumen Technologies, Inc. Governance Coc Protection Update

Lumen Unifies Executive Severance, Removes CEO Non-Compete

Market cap : at edition (Oct 23, 2026) $4.6B

Lumen Technologies consolidated its executive severance arrangements on October 22, 2026, terminating individual change-of-control agreements with CEO Kate Johnson and other named executive officers and replacing them with a unified plan. The company states no material change to existing benefits resulted. The most substantive disclosed change is the removal of Johnson's non-competition covenant, which Lumen attributes to compliance with Washington state law set to take effect June 30, 2027. Under the new plan, Johnson retains a 2.5x cash severance multiplier on change-of-control termination, while other NEOs receive 2x.

RCAT Red Cat Holdings, Inc. M&A Merger Pending

Red Cat Launches ~$220 Million All-Cash Bid for Austrian Engine Maker Steyr Motors

Market cap : at edition (Oct 23, 2026) $667M

Red Cat Holdings has agreed to acquire Steyr Motors AG, an Austrian manufacturer of high-performance military and marine engines, via an all-cash tender offer at EUR 39.00 per share for all 5,251,261 outstanding shares — total consideration of approximately EUR 204.8 million (~$220 million). The deal, announced October 21, 2026, is Red Cat's largest acquisition to date and would consume the bulk of the $325.6 million cash balance the company held as of June 30, 2026 — itself the product of a $258.75 million equity raise completed just five months earlier. The offer is conditioned on a minimum 50%-plus-one-share acceptance threshold and foreign direct investment clearances in four jurisdictions by June 30, 2027; Steyr's anchor shareholder B&C Holding, holding approximately 15% of the capital, has irrevocably committed to tender.

AKBA Akebia Therapeutics, Inc. Distressed Listing At Risk

Akebia Receives Nasdaq Bid-Price Deficiency Notice as Stock Falls Below $1

Market cap : at edition (Oct 23, 2026) $156M

Nasdaq notified Akebia Therapeutics on October 21, 2026 that its stock had closed below $1.00 for 30 consecutive business days, giving the company until April 19, 2027 to regain compliance or face delisting proceedings. The deficiency arrived despite a positive clinical readout — the VOICE trial was stopped early in June for efficacy after demonstrating Vafseo's superiority over ESAs on a composite mortality-and-hospitalization endpoint. The stock's sub-$1 status reflects investor concern about accelerating Auryxia revenue erosion from generics, which has more than offset Vafseo's sequential commercial growth. Chief Commercial Officer Nicholas Grund simultaneously announced his resignation, effective November 6, though he will remain as a paid consultant through April 2027.

RCUS Arcus Biosciences, Inc. Capital Capital Build

Arcus Raises $270M in Second Offering Within Twelve Months

Market cap : at edition (Oct 23, 2026) $2.5B

Arcus Biosciences closed a $270 million public equity offering on October 23, 2026, selling 16.4 million shares at $17.50 each — the second time in roughly twelve months the company has raised almost exactly that amount. The underwriting agreement was signed the day after Arcus published a preliminary Q3 cash balance of approximately $694 million and one day after presenting new casdatifan clinical data. As recently as August, management guided to ending 2026 with approximately $600 million in cash and maintained a runway through at least the second half of 2028 — a figure the raise now substantially exceeds. With two Phase 3 studies ramping and a first-line kidney cancer trial expected to initiate by year-end, the additional capital appears aimed at funding a materially expanded clinical footprint following the collapse of the Gilead collaboration.

MEI Methode Electronics, Inc. Governance Management Transition

Methode Electronics CFO to Absorb Accounting Role After CAO Exit

Market cap : at edition (Oct 23, 2026) $451M

Chief Accounting Officer Stacie Schulz resigned from Methode Electronics effective October 30, 2026, citing a desire to pursue other opportunities; the filing explicitly states the departure involves no disagreement with auditors or management on any matter of accounting principles, financial statement disclosure, or internal controls. CFO Laura Kowalchik will absorb the principal accounting officer designation, with no replacement CAO named. The change arrives five months after the SEC staff closed its investigation into the company without recommending an enforcement action, and as Methode continues a multi-quarter financial recovery — full-year fiscal 2026 net loss narrowed to $35.7 million from $62.6 million the prior year, with adjusted EBITDA up 60.5% to $68.2 million.

XRPN Evernorth Holdings, Inc. Capital Serial Equity Issuance

Evernorth Sets Up Dilutive Equity Facility Fourteen Days After SPAC Debut

Market cap : at edition (Oct 23, 2026) $344M

Fourteen days after completing its SPAC merger, XRP treasury company Evernorth Holdings (XRPN) signed a committed equity facility with CF Principal Investments, a Cantor affiliate, allowing the company to sell up to 5,218,935 Class A shares at 97% of VWAP over 14 months. A non-refundable $521,893.50 commitment fee is owed once the resale registration statement is declared effective. The facility lands on top of $30 million in 4% Convertible PIK Notes that closed simultaneously with the merger — notes structured so interest capitalizes into principal rather than paying cash, growing the debt load without immediate cash cost.

PBT Permian BASIN Royalty TRUST M&A Merger Pending

PBT Unitholders to Vote on Converting Passive Trust Into Active Corporation

Market cap : at edition (Oct 23, 2026) $1.6B

A November 23, 2026 unitholder vote will determine whether Permian Basin Royalty Trust — a passive, passively managed royalty vehicle — is dissolved and its assets merged with Blackbeard Holdings to form a new publicly traded company, PBT Land and Minerals, Inc. The ballot includes adoption of a management incentive plan for the successor entity, confirming this is a wholesale transformation rather than a simple asset transfer. The path to the vote required a court order in May 2026 that stripped the Trust's original 75%-approval requirement from the indenture, replacing it with a majority-of-quorum standard that SoftVest and its allies, holding more than 15% of units, are positioned to clear.

ARDT Ardent Health, Inc. Governance Conflict of interest

Ardent Health Strips Former CEO of $4.5 Million Over Undisclosed Third-Party Pay

Market cap : at edition (Oct 23, 2026) $1.7B

Ardent Health's board retroactively classified Martin Bonick's June 2026 departure as a termination for Cause, finding he failed to fully disclose compensation received from third parties as required by company policy. The reclassification, formalized on October 19, 2026, strips Bonick of approximately $4.5 million in unpaid cash severance and cancels all his outstanding unvested performance-based restricted stock units. The company has reserved the right to pursue additional remedies. The filing does not identify the third parties or describe the nature of the undisclosed compensation.

PHAT Phathom Pharmaceuticals, Inc. Legal Existential License Dispute

Generic Maker Sues FDA Over VOQUEZNA's GAIN Act Exclusivity Extension

Market cap : at edition (Oct 23, 2026) $567M

BDR Pharmaceuticals International filed suit against the FDA in the U.S. District Court for the District of Columbia on October 23, 2026, challenging the agency's refusal to receive a generic drug application for VOQUEZNA and alleging the FDA improperly applied the GAIN Act to extend Phathom's New Chemical Entity exclusivity through May 3, 2032. Phathom, which is not a named defendant, contends the FDA acted correctly and says it will defend its exclusivity. VOQUEZNA is Phathom's only commercial product, the sole basis for full-year 2026 guidance of $310–325 million in net revenues, and the company's own risk disclosures acknowledge that a BDR victory would allow FDA to receive and potentially approve generics earlier than currently anticipated.

Conduent's $447M Refinancing Carries a Year-End Default Trigger